Close

RL-6-Me-7-OH

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Reduced 6-(hydroxymethyl)-8-(1-D-ribityl)lumazine is the pteridine that is lumazine reduced across the C-6,C-7-double bond and substituted with a hydroxymethyl group at C-6 and a 1-D-ribityl group at N-8. It derives from a ribitol and a lumazine.
  • TCR Vector Products

  • TCR Cell Products

  • TCR Viral Particles

Loading...
  • Target Species:
  • TCR Clone:
  • Host Species:
  • Epitope:
  • Allele:
  • Vector Type:
CAT Product Name Target Species TCR Clone Host Species Epitope Allele Vector Type Inquiry & Datasheet
TCR-YC1044 Human anti-RL-6-Me-7-OH T cell receptor (A-F7), pCDTCR1 Salmonella enterica subsp. enterica serovar Typhimurium A-F7 Human 7-hydroxy-6-methyl-8-(1-D-ribityl)lumazine human MR1 Lentiviral vector   Add to Cart   Datasheet
TCR-YC1045 Human anti-RL-6-Me-7-OH T cell receptor (YC50), pCDTCR1 Human YC50 Human reduced 6-hydroxymethyl-8-d-ribityllumazine MR1 K43A Lentiviral vector   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.